Santhera Pharmaceutical Holding Ltd

Santhera Pharmaceuticals

Santhera is focusing on the development and commercialization of innovative treatments of mitochondrial and neuromuscular diseases. This area of high unmet medical need includes many orphan and niche indications with no current therapy. Strategically, Santhera focuses on RaxoneŽ/CatenaŽ (INN: idebenone) in mutliple indications.

Products & Pipeline

Santhera's first product RaxoneŽ has received European marketing authorization in Leber's Hereditary Optic Neuropathy. The compound is also being developed in Duchenne Muscular Dystrophy, and primary Progressive Multiple Sclerosis. Omigapil, a second compound, is in clinical development to treat Congenital Muscular Dystrophy.

Clinical Development Programs

Currently, the NIH are investigating the safety and efficacy of RaxoneŽ/CatenaŽ in a Phase II trial (IPPoMS) as potential therapy of primary progressive Multiple Sclerosis. Also at the NIH, a Phase I study (CALLISTO) is being conducted to investigate the omigapil in pediatric and adolescent patients suffering from Congenital Muscular Dystrophy.

Latest News

November 11, 2015
Santhera Reports New Data and Updates on Regulatory Filings for RaxoneŽ (idebenone) in Duchenne Muscular Dystrophy (DMD)
October 22, 2015
Santhera and Parent Project Muscular Dystrophy (PPMD) Announce Results of Benefit / Risk Survey in patients with Duchenne Muscular Dystrophy (DMD)
October 01, 2015
Santhera launches RaxoneŽ in its first EU market